MetaCap

ProQR Therapeutics N.V. (PRQR) vs Veraxa Biotech (VRXA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ProQR Therapeutics N.V. (PRQR) has outperformed Veraxa Biotech (VRXA) over the past year, losing 49.5% versus a loss of 90.1%. Veraxa Biotech is the larger company by market cap ($147.1 million vs $147.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PRQR-49.51%VRXA-90.10%
+147%+22%-102%
Nov 21, 20251 yearNov 20, 2026
PRQR-46.67%VRXA-89.58%
+133%+16%-101%
Sep 30, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PRQR versus VRXA key metrics
MetricPRQRVRXA
Share price$1.04$1.04
Market cap$146.98M$147.06M
1-day change-0.95%+0.97%
YTD return-48.51%-90.25%
1-year return-49.51%-90.10%
5-year return-85.54%—
EPS (TTM)$-0.43$-0.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.49$27.36
52-week low$1.00$0.90
Distance from 52-week high-58.15%-96.20%
Analyst consensusstrong_buy—
Avg. price target upside+626.92%—
Average volume793.64K267.82K
Shares outstanding141.33M141.41M
Employees186—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRQR has outperformed VRXA by 40.6 percentage points over the past year.

About ProQR Therapeutics N.V.

PRQR stock →

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees

About Veraxa Biotech

VRXA stock →

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.

Health Care · Biotechnology: Pharmaceutical Preparations

PRQR vs VRXA FAQ

Which is bigger, ProQR Therapeutics N.V. or Veraxa Biotech?

Veraxa Biotech (VRXA) is larger, with a market capitalization of $147.06M compared with $146.98M for ProQR Therapeutics N.V. (PRQR).

Which stock has performed better over the past year, PRQR or VRXA?

PRQR returned -49.51% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.

Are ProQR Therapeutics N.V. and Veraxa Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons